{"DataElement":{"publicId":"3015243","version":"1","preferredName":"Patient Agent Adverse Event Torsades De Pointes Exclusion Criteria Ind-2","preferredDefinition":"the yes/no indicator related to elements of a patient'smedical history which would prevent an individual from participating in a specific clinical trial from agent with accepted risk of causing an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline.","longName":"3015241v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3015241","version":"1","preferredName":"Patient Agent Adverse Event Torsades De Pointes Exclusion Criteria","preferredDefinition":"information related to elements of a patient'smedical history which would prevent an individual from participating in a specific clinical trial from agent with accepted risk of causing an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline.","longName":"2233604v1.0:3015239v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3015239","version":"1","preferredName":"Agent Adverse Event Torsades De Pointes Exclusion Criteria","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:An atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline. In addition the QRS complex displays a periodic waxing and waning of amplitude on the electrogram. (NCI):Elements of a personal medical history which would prevent an individual from participating in a specific clinical trial.","longName":"C1708:C41331:C50779:C16148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Torsades De Pointes by ECG Finding","conceptCode":"C50779","definition":"An electrocardiographic finding of an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline, occurring in the setting of a prolonged QT interval. In addition, the QRS complex displays a periodic waxing and waning of amplitude on the electrocardiogram.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Exclusion Criteria","conceptCode":"C16148","definition":"Elements of a personal medical history which would prevent an individual from participating in a specific clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"804A157C-F110-AFBA-E040-BB89AD433482","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"ONEDATA","dateModified":"2010-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"804A157C-F121-AFBA-E040-BB89AD433482","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Any of the following Category","type":"Preferred Question Text","description":"Any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes <=7 days prior to registration: Quinidine, procainamide, disopyramide; Amiodarone, sotalol, ibutilide, dofetilide;  Erythromycin, clarithromycin; Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide; Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the patient discontinued and agreed to sustain from using any medications that have a known risk of Torsades de Pointes (see Appendix IV) 14 days prior to starting OSI-906, during treatment with OSI-906 and until 7 days after final treatment with OSI-906","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes <=7 days prior to registration: Quinidine, procainamide, disopyramide; Amiodarone, sotalol, ibutilide, dofetilide; Erythromycin, clarithromycin; Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide; Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine; Prochlorperazine","url":null,"context":"CTEP"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"804A9C91-166F-E1A1-E040-BB89AD430FE2","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"DWARZEL","dateModified":"2012-07-18","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}